Status:
RECRUITING
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Lead Sponsor:
Takeda
Conditions:
Acquired Hemophilia A
Eligibility:
All Genders
18+ years
Brief Summary
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting condition...
Detailed Description
This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.
Eligibility Criteria
Inclusion
- Participants with AHA.
- Participants who are determined to have the clinical need to receive Obizur treatment.
- Participants aged 18 years or older at time of initiation of Obizur treatment.
- Participants agreed to participate in the study and voluntarily signed the informed consent.
Exclusion
- Participants with hypersensitivity to any of the components of this drug.
- Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
- Participants for whom Obizur treatment is contraindicated as per product label.
- Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.
Key Trial Info
Start Date :
July 22 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT06550882
Start Date
July 22 2025
End Date
September 30 2026
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyung Hee University Hospital at Gangdong
Seoul, South Korea, 05278